BSE Live
Apr 15, 16:01Prev. Close
344.95
Open Price
348.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 15, 15:59Prev. Close
345.00
Open Price
347.90
Bid Price (Qty.)
350.35 (623)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Biocon (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 436.30 | 492.70 | 238.50 | 519.30 | 368.60 | |
| Net CashFlow From Operating Activities | 387.10 | 109.50 | 355.20 | 185.80 | 208.50 | |
| Net Cash Used In Investing Activities | -212.90 | 310.90 | -555.50 | 110.40 | -321.10 | |
| Net Cash Used From Financing Activities | -128.90 | -208.20 | -54.60 | -238.30 | 73.00 | |
| Foreign Exchange Gains / Losses | 24.00 | 4.40 | 2.40 | -6.40 | 7.80 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 69.30 | 216.60 | -252.50 | 51.50 | -31.80 | |
| Cash And Cash Equivalents Begin of Year | 305.70 | 89.10 | 341.60 | 290.10 | 321.90 | |
| Cash And Cash Equivalents End Of Year | 375.00 | 305.70 | 89.10 | 341.60 | 290.10 |
08.04.2026
31.03.2026
11.03.2026
17.02.2026
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth